Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment
出版年份 2015 全文链接
标题
Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment
作者
关键词
-
出版物
Frontiers in Immunology
Volume 6, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2015-02-09
DOI
10.3389/fimmu.2015.00046
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma
- (2015) Alan E. Siroy et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The clinical response to vemurafenib in a patient with a rare BRAF V600DK601del mutation-positive melanoma
- (2014) Stéphanie Trudel et al. BMC CANCER
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma
- (2014) L. Ferrari de Andrade et al. CANCER RESEARCH
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Clinical use of dendritic cells for cancer therapy
- (2014) Sébastien Anguille et al. LANCET ONCOLOGY
- Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma
- (2014) Devin B Lowe et al. OncoImmunology
- Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
- (2014) Anna Kreutzman et al. OncoImmunology
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Melanoma genetics: the other side
- (2013) Sabina Bis et al. CLINICS IN DERMATOLOGY
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
- (2013) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody Depletion by Bortezomib through Blocking of Antigen Presentation
- (2013) Se Jin Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of CD8+T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)
- (2013) Daphné Benteyn et al. Biomed Research International
- Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
- (2013) M. K. Callahan et al. Cancer Immunology Research
- Peptide-based anticancer vaccines
- (2013) Yared Hailemichael et al. OncoImmunology
- Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40
- (2012) Y. Yang et al. BLOOD
- Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma
- (2012) Nicolai Leonhartsberger et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Lessons from Cancer Immunoediting in Cutaneous Melanoma
- (2012) Mariana Aris et al. Clinical & Developmental Immunology
- Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
- (2012) J. S. Khalili et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
- (2012) C. Liu et al. CLINICAL CANCER RESEARCH
- 1102 In Vitro Enhancement of NK Cell Activity of Metastatic Melanoma Patients With IFN-alpha Alone as Opposed to its Combination With 13-cis Retinoic Acid is Associated With Modulation of NKG2D and CD161 Activating Receptor Expression
- (2012) G. Konjevic et al. EUROPEAN JOURNAL OF CANCER
- BRAF inhibitor activity in V600R metastatic melanoma
- (2012) Oliver Klein et al. EUROPEAN JOURNAL OF CANCER
- Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma
- (2012) Wesley O. Greaves et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
- (2012) M. L. Huber et al. JNCI-Journal of the National Cancer Institute
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Melanoma genome sequencing reveals frequent PREX2 mutations
- (2012) Michael F. Berger et al. NATURE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial
- (2012) CHIE OSHITA et al. ONCOLOGY REPORTS
- Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
- (2012) James S. Wilmott et al. OncoImmunology
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer
- (2011) T. M. Beer et al. CLINICAL CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- MART-1- and gp100-Expressing and -Non-Expressing Melanoma Cells Are Equally Proliferative in Tumors and Clonogenic In Vitro
- (2011) Mariana Aris et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
- (2011) Sergey I Nikolaev et al. NATURE GENETICS
- BRAF targeted therapy changes the treatment paradigm in melanoma
- (2011) Antoni Ribas et al. Nature Reviews Clinical Oncology
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis
- (2011) Andreas Draube et al. PLoS One
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- A phase 2 trial of dasatinib in advanced melanoma
- (2010) Harriet M. Kluger et al. CANCER
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations
- (2010) B. Comin-Anduix et al. CLINICAL CANCER RESEARCH
- Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
- (2010) M. J. Besser et al. CLINICAL CANCER RESEARCH
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients
- (2010) Gordana Konjević et al. MELANOMA RESEARCH
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression
- (2010) R. A. Madan et al. ONCOLOGIST
- Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients
- (2009) Nadege Bercovici et al. JOURNAL OF IMMUNOTHERAPY
- The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
- (2009) Rikke Bæk Sørensen et al. PLoS One
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
- (2008) Mark E. Dudley et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF Secretion is Inhibited by Interferon-Alpha in Several Melanoma Cell Lines
- (2008) Ene T. Raig et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Interleukin-2: Evaluation of Routes of Administration and Current Delivery Systems in Cancer Therapy
- (2008) Mohamed A. Shaker et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression
- (2008) Erika M von Euw et al. Journal of Translational Medicine
- Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
- (2008) Oliver Hantschel et al. LEUKEMIA & LYMPHOMA
- Antigens for cancer immunotherapy
- (2008) Michelle A. Neller et al. SEMINARS IN IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started